Satellos Bioscience (MSLE) Accounts Payables (2023 - 2026)

Satellos Bioscience (MSLE) has reported Accounts Payables for 4 consecutive years, with $4.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $4.6 million (changed N/A YoY), while the FY2025 annual figure was $4.1 million, up 14.57% from the prior year.
• Accounts Payables advanced to $4.6 million in Q1 2026 per MSLE's latest filing, from $4.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.6 million in Q1 2026 and bottomed at $2.7 million in Q4 2023.
• Historically, Accounts Payables has averaged $3.8 million across 4 years, with a median of $3.9 million in 2024.
• Annual changes were most pronounced in 2024 — Accounts Payables jumped 38.63% — and 2025, when it climbed 11.24%.
• Satellos Bioscience's Accounts Payables stood at $2.7 million in 2023, then soared by 38.63% to $3.7 million in 2024, then gained by 11.24% to $4.1 million in 2025, then climbed by 11.16% to $4.6 million in 2026.
• Business Quant data shows MSLE's Accounts Payables at $4.6 million in Q1 2026, $4.1 million in Q4 2025, and $3.7 million in Q4 2024.